Study of Pemigatinib for Patients with Recurrent or Metastatic Solid Tumors with FGFR Gene Alteration

1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called pemigatinib on certain types of cancer. Specifically, it targets patients with solid tumors that have a change in a gene known as FGFR. These tumors are either recurring or have spread to other parts of the body, which is known as metastatic cancer. The study is looking at cases where these genetic changes are not already being treated with approved medications in France.

The purpose of the study is to see how well pemigatinib works in slowing down or reducing the growth of these tumors. Participants in the study will take pemigatinib in the form of tablets. Some participants may receive a placebo instead. The study will monitor the effects of the medication over a period of time to understand its impact on tumor growth and overall health. The trial will also assess the safety and any side effects of the treatment.

Throughout the study, participants will undergo regular check-ups and imaging tests like MRI or CT scans to track the progress of their cancer. The study aims to provide valuable information on whether pemigatinib can be an effective treatment option for patients with these specific genetic changes in their tumors. The trial is expected to continue until 2028, with recruitment starting in late 2024.

1 beginning of treatment

Upon joining the clinical trial, you will begin treatment with a medication called pemigatinib. This medication is provided in the form of tablets and is taken orally.

The dosage of pemigatinib is 4.5 mg per tablet. You will be instructed on the specific frequency and duration of administration by the medical team overseeing the trial.

2 regular monitoring

Throughout the trial, your health and response to the treatment will be closely monitored. This includes regular medical check-ups and assessments to evaluate the effectiveness of the treatment on tumor growth.

You may undergo imaging tests such as CT or MRI scans to measure any changes in the size of the tumor. These tests will be conducted at specified intervals to track your progress.

3 evaluation of response

The primary goal of the trial is to assess the efficacy of pemigatinib in reducing tumor growth. Your response to the treatment will be evaluated based on the changes in tumor size and growth rate.

The medical team will determine if there is an objective response, which means a significant reduction in tumor size or growth rate, as compared to the measurements taken before the treatment started.

4 safety and side effects

Your safety is a priority during the trial. Any side effects or adverse reactions to the medication will be monitored and documented.

You will be asked to report any symptoms or changes in your health to the medical team, who will provide guidance and support to manage any side effects.

5 completion of trial

The trial is expected to continue until the estimated end date in May 2028. Your participation may last until the trial is completed or until the medical team determines it is appropriate for you to stop.

Upon completion of the trial, you will have a final assessment to evaluate the overall impact of the treatment on your condition.

Who Can Join the Study?

Must have a solid tumor confirmed by a test called histology or cytology.
Must have adequate blood function:
- ANC (a type of white blood cell) greater than 1.5 x 10⁹/L
- Platelets (cells that help with blood clotting) greater than 75 x 10⁹/L
- Hemoglobin (a protein in red blood cells) greater than 9.0 g/dL. Blood transfusion is allowed if done at least 2 weeks before starting treatment.
Must have adequate liver function:
- ALT and AST (liver enzymes) less than 2.5 times the upper limit of normal (ULN), or less than 5 times ULN if there are liver metastases.
- Total bilirubin (a substance made by the liver) less than 1.5 times ULN, or less than 2.5 times ULN if there is Gilbert’s syndrome or liver metastases.
- ALP (another liver enzyme) less than 3 times ULN.
Must have adequate kidney function: serum creatinine clearance greater than 30 mL/minute, calculated using a formula called Cockroft-Gault.
Serum phosphate levels must be less than or equal to the normal limit, and serum calcium levels must be within the normal range.
Potassium levels must be within the normal range. Supplements can be used to correct potassium levels during screening.
Men and women who can have children must agree to use effective birth control during the study and for at least one week after the last dose of the study drug. Men must also agree not to donate sperm, and women must agree not to donate eggs during this time.
Women who can have children must have a negative pregnancy test within 14 days before starting treatment.
Must be part of a social security system.
Must sign a written consent form before any study procedures. If unable to sign, a trusted person can sign on their behalf.
Must have a type of cancer with a specific genetic change called FGFR1, 2, or 3 fusion/rearrangement or mutation.
Must be 18 years or older.
Must have an ECOG performance status of 2 or less. This is a scale that measures how well a person can perform daily activities.
Must not have any other suitable treatment options and must be considered to benefit from an FGFR inhibitor by their doctor.
Must have an estimated life expectancy of more than 3 months.
Must have measurable disease according to a standard called RECIST1.1. Tumors in areas that have been treated before can be measured if they have clearly grown.
Must have two tumor evaluations before treatment, done at least 4 weeks apart and no more than 3 months apart, using the same method (CT or MRI) and without any cancer treatment during this time.
Must have a minimal increase in tumor growth rate of 0.1 mm/day between the pre-treatment and baseline scans, as assessed by the doctor.

Who Cannot Join the Study?

Patients who have a type of cancer that is already approved for treatment with any selective FGFR inhibitor in France cannot participate.
Patients who do not have a specific genetic change in their cancer called an FGFR alteration (which includes fusion, rearrangement, or activating mutation) cannot participate.
Patients who are not able to understand or comply with the study requirements cannot participate.
Patients who have other serious health conditions that could interfere with the study cannot participate.
Patients who are pregnant or breastfeeding cannot participate.
Patients who have had another cancer treatment within a certain period before the study starts cannot participate.
Patients who have an active infection or other uncontrolled medical condition cannot participate.
Patients who have a known allergy to the study medication cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Institut Gustave Roussy	Villejuif	France
Oncopole Claudius Regaud	Toulouse	France
Centr Georges Francois Leclerc	Dijon	France
Centre Jean Perrin	Clermont Ferrand	France
Institut De Cancerologie De Lorraine	Vandoeuvre Les Nancy	France
Centre Hospitalier Universitaire De Bordeaux	Bordeaux	France
Centre Hospitalier Regional Et Universitaire De Brest	Brest	France
CHU Grenoble Alpes	La Tronche	France

Other Sites

Site Name	City	Country
Centre Antoine Lacassagne	Nice	France
Centre Hospitalier Universitaire Rouen	Rouen	France
Centre Hospitalier Universitaire De Poitiers	Poitiers	France
Institut De Cancerologie Strasbourg Europe	STRASBOURG, Alsace	France
Centre Hospitalier Universitaire Amiens Picardie	Amiens	France
Centre Hospitalier Lyon Sud	Pierre Benite	France
Institut Sainte Catherine	Avignon	France
Institut de Cancérologie de l’Ouest	Saint-Herblain	France
Centre Francois Baclesse	Caen	France
Centre De Lutte Contre Le Cancer Eugene Marquis	Rennes	France
Cxmkxb Lmmg Biruhp	Lyon	France
Ctkugp Hxtlbuzcxni Uqwveuvwjjjbz Rbyup	Reims	France
Imbpaojl Mpkcqcsron Mhnnimruys	Paris	France
Pnsuapmindup Srqfbnzweu	Compiegne	France
Gkjhpy Hrqkpacsgtp Pwbgpp Dp Sut Ds L Ozon	Creil	France
Ibwzrgmr Bnumamvn	Bordeaux	France
Aiqxkyyqcs Phpwvrrx Htyhhnoj De Mgrbmwhrx	Marseille	France
Igdloghb ds Cigbovznnxkq Hsznqcnxbip Uyuskmouvfetc dl Sqvqx Ejqrxjm (jtjsbzo	Saint Priest En Jarez	France
Imeuvlrp Psavdbcnzbqoges Cxurhi Cuvtjb	Marseille	France
Cqonbw Obxxn Lbwjxvj	Lille	France
Ibyflnbx Cpxbo	Paris	France

Trial status

Country	Status	Recruitment Start
France	Recruiting	01.11.2024

Trial locations

Investigated drugs:

Pemigatinib

Pemigatinib is a medication being studied for its ability to slow down or stop the growth of certain types of cancer. It is specifically being tested in patients who have cancers with changes in a gene called FGFR. These changes can make cancer cells grow uncontrollably. Pemigatinib works by blocking the activity of the FGFR gene, which may help to stop the cancer from growing or spreading. This medication is being used alone, without any other cancer treatments, to see how effective it is in treating these specific types of cancer. Patients in the trial have cancers that have come back or spread to other parts of the body, and the goal is to see if pemigatinib can help manage their disease.

Recurrent or metastatic solid cancer with FGFR alteration – This type of cancer involves solid tumors that have either returned after treatment or spread to other parts of the body. It is characterized by changes in the FGFR genes, which can include fusions, rearrangements, or activating mutations. These genetic alterations can lead to abnormal cell growth and division. The progression of the disease is marked by the growth and spread of tumors, which can affect various organs and tissues. The behavior of the cancer can vary depending on the specific FGFR alteration and the type of solid tumor involved. The disease can lead to changes in tumor size and growth rate over time.

Trial ID:

2024-512729-10-00

Protocol code:

UC-GMP-2305

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of Pemigatinib for Patients with Recurrent or Metastatic Solid Tumors with FGFR Gene Alteration

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?